国元证券股份有限公司 关于 杭州奥泰生物技术股份有限公司 2022年限制性股票激励计划 首次授予第三个归属期 及 预留授予第二个归属期 符合归属条件事项 之 独立财务顾问报告 二〇二五年八月 | 一、释义 | 3 | | --- | --- | | 二、声明 | 5 | | 三、基本假设 | 6 | | 四、本次激励计划已履行的审批程序 | 7 | | 五、本次激励计划的归属情况 | 10 | | 六独立财务顾问意见 | 14 | 国元证券股份有限公司 独立财务顾问报告 一、释义 在本报告中，如无特殊说明，下列简称具有如下含义： | 释义项 | | 释义内容 | | --- | --- | --- | | 公司、本公司、上市公司、 | 指 | 杭州奥泰生物技术股份有限公司 | | 奥泰生物 | | | | 限制性股票激励计划、本次 | | 杭州奥泰生物技术股份有限公司2022年限制性股票激励 | | 激励计划 | 指 | 计划 | | 《2022年激励计划》 | 指 | 《杭州奥泰生物技术股份有限公司2022年限制性股票激 | | | | 励计划（草案）》 | | | | 《国元证券股份有限公司关于杭州奥泰生 ...

礼丰律师事务所 关于杭州奥泰生物技术股份有限公司 2022 年限制性股票激励计划 授予价格调整、首次授予部分第三个归属期及预留授予部分第二 个归属期归属条件成就及部分限制性股票作废事项之 法律意见书 致：杭州奥泰生物技术股份有限公司 上海礼丰律师事务所(以下简称"本所")接受杭州奥泰生物技术股份有限公司 (以下简称"奥泰生物"或"公司")的委托，指派本所律师根据《中华人民共和国公 司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以下简称"《证券法》")、 中国证券监督管理委员会(以下简称"中国证监会")《上市公司股权激励管理办法》 (以下简称"《管理办法》")等法律、法规、规范性文件(以下统称"法律法规")及《杭 州奥泰生物技术股份有限公司章程》(以下简称"《公司章程》")的规定就公司实 施 2022 年限制性股票激励计划(以下简称"本激励计划")的授予价格调整(以下简 称"本次调整")、首次授予部分第三个归属期及预留授予部分第二个归属期归属 条件成就(以下简称"本次归属")及部分限制性股票作废(以下简称"本次作废")所 涉及的相关事项出具本法律意见书。 1 本所及经办律师依据《证券法》《律师事务 ...

证券代码：688606 证券简称：奥泰生物 公告编号：2025-029 杭州奥泰生物技术股份有限公司 第三届监事会第十四次会议决议公告 2、审议通过《关于<2022 年限制性股票激励计划首次授予第三个归属期及预留授 予第二个归属期符合归属条件>的议案》 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况： 杭州奥泰生物技术股份有限公司（以下简称"公司"）第三届监事会第十四次会 议（以下简称"本次会议"）于 2025 年 7 月 31 日以电子邮件的形式发出会议通知， 于 2025 年 8 月 8 日上午 9：30 在公司会议室以现场会议的方式召开。会议应出席监事 3 名，实际出席监事 3 名。本次会议的召集、召开程序和方式符合《中华人民共和国公 司法》（以下简称"《公司法》"）等法律法规以及《杭州奥泰生物技术股份有限公 司章程》的有关规定，会议决议合法、有效。 二、监事会会议审议情况： 会议由监事会主席高跃灿先生主持召开，全体与会监事经认真审议和表决，形成 以下决议： 1、审议通过《关于<调整 2022 ...

本次激励计划首次授予第三个归属期拟归属的 94 名激励对象及预留授予第 二个归属期拟归属的 18 名激励对象，符合《公司法》等法律法规和规范性文件 以及《公司章程》规定的任职资格，符合《管理办法》《上市规则》等法律法规 和规范性文件规定的激励对象条件，符合《杭州奥泰生物技术股份有限公司 2022 年限制性股票激励计划（草案）》规定的激励对象范围，其作为公司本次激励计 划激励对象的主体资格合法、有效，激励对象获授限制性股票的归属条件已成就。 因此，监事会同意本次激励计划首次授予第三个归属期及预留授予第二个归 属期的归属名单。 杭州奥泰生物技术股份有限公司监事会 2025 年 8 月 8 日 杭州奥泰生物技术股份有限公司 监事会关于公司 2022 年限制性股票激励计划首次授予第三 个归属期及预留授予第二个归属期归属名单的核查意见 杭州奥泰生物技术股份有限公司（以下简称"公司"）监事会依据《中华人 民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》《上 市公司股权激励管理办法》（以下简称"《管理办法》"）、《上海证券交易所 科创板股票上市规则》（以下简称"《上市规则》"）、《科创板上市公司自律 监 ...

证券代码：688606 证券简称：奥泰生物 公告编号：2025-028 杭州奥泰生物技术股份有限公司 第三届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 2、审议通过《关于<2022 年限制性股票激励计划首次授予第三个归属期及 预留授予第二个归属期符合归属条件>的议案》 杭州奥泰生物技术股份有限公司（以下简称"公司"）第三届董事会第十四 次会议（以下简称"本次会议"）于 2025 年 7 月 31 日以电子邮件的方式发出会 议通知，于 2025 年 8 月 8 日上午 11：00 在公司会议室以现场与通讯相结合的方 式召开。本次会议由公司董事长高飞先生召集并主持，本次会议应出席董事 5 名，实际出席董事 5 名，高级管理人员列席了本次会议。本次会议的召开符合《中 华人民共和国公司法》等法律法规以及《杭州奥泰生物技术股份有限公司章程》 的有关规定，会议决议合法、有效。 二、董事会会议审议情况 经与会董事充分讨论，审议并表决如下议案： 1、审议通过《关于<调整 2022 年 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aotai Biological Technology Co., Ltd, indicating a low PE ratio compared to industry averages [1][2] - As of August 6, Aotai's stock closed at 74.69 yuan, with a rolling PE ratio of 18.57, marking a new low in 85 days, and a total market capitalization of 5.921 billion yuan [1] - The average PE ratio for the medical device industry is 53.93, with a median of 37.81, positioning Aotai at 41st among its peers [1][2] Group 2 - For Q1 2025, Aotai reported revenue of 208 million yuan, a year-on-year increase of 4.28%, and a net profit of 61.216 million yuan, reflecting a 36.68% increase [2] - The company's gross profit margin stands at 55.63%, indicating strong profitability relative to its revenue [2] - Aotai's main business focuses on the research, production, and sales of in vitro rapid diagnostic reagents, with key products in infectious diseases, drug abuse, women's health, COVID-19 testing, tumors, and myocardium [1]

内容概要：药物检测设备作为医疗检测设备的重要细分领域，国家高度重视药物检测设备的发展，将其 视为保障药品安全、提升医疗质量、维护公共健康的重要技术支撑。其技术进步直接受益于医疗检测设 备行业的整体发展。近年来，国家出台了一系列政策措施支持医疗装备行业发展。如《"十四五"医疗装 备产业发展规划》《关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见》等等。在国 家政策引导、资金投入、技术攻关等多方面推动下，我国药物检测设备取得快速发展。据统计，2024年 我国医疗检测设备市场规模为435.90亿元，药物检测设备市场规模为68.38亿元；预计2025年我国医疗检 测设备市场规模将达520亿元，药物检测设备市场规模约69.5亿元。 上市企业：聚光科技[300203]、奥泰生物[688606]、华大智造[688114] 二、药物检测设备行业发展现状 药物检测设备作为医疗检测设备的重要细分领域，其技术进步直接受益于医疗检测设备行业的整体发 展。医疗检测设备是医疗装备产业的核心组成部分，近年来，国家出台了一系列政策措施支持医疗装备 行业发展。如《"十四五"医疗装备产业发展规划》《关于全面深化药品医疗器械监管改革促 ...

Group 1: Overview of Chikungunya Fever - Chikungunya virus is spreading globally, with 119 countries reporting cases and approximately 5.5 million people at risk of infection [1] - In Foshan, Guangdong Province, over 4,000 confirmed cases have been reported, primarily mild cases [1] Group 2: Symptoms and Treatment - Chikungunya fever is characterized by high fever and severe joint pain, particularly affecting small joints [2] - There is currently no specific treatment or widely used vaccine; management is primarily supportive, focusing on symptom relief [3] Group 3: Market Response and Company Involvement - Investors are inquiring about companies with products related to Chikungunya fever, focusing on mosquito repellent products, testing kits, and antipyretic and analgesic medications [4] - Companies like Rainbow Group, Runben Co., and Weigao Medical have reported an increase in sales of mosquito repellent products [5][6] - Pharmaceutical companies such as Renhe Pharmaceutical and Xinhua Pharmaceutical have indicated they offer products for fever and pain relief [7] Group 4: Testing Products - Companies like Kehua Bio, YHLO Biotech, and Shuoshi Bio have developed testing kits for Chikungunya virus [8] - YHLO Biotech has a rapid screening kit for Chikungunya, currently used for research purposes [8] - The market interest in these companies has led to notable stock price increases since the news of the outbreak [8]

Group 1 - The World Health Organization (WHO) reports that 119 countries and regions have identified the spread of Chikungunya virus, with approximately 5.5 million people at risk, potentially leading to widespread outbreaks that could strain health systems [1] - Several A-share listed companies have made strategic moves in response to the Chikungunya virus, including Ayhuilong, Shuoshi Biology, Aotai Biology, Rendu Biology, and Rainbow Group, who have shared their plans on the stock exchange interaction platform [1] Group 2 - Chikungunya fever is primarily transmitted by Aedes mosquitoes, with symptoms including fever, rash, and joint pain. Measures such as eliminating breeding sites and insect extermination can help interrupt transmission [2] - The Guangdong Province reported a local outbreak of Chikungunya fever linked to imported cases, with 3,645 confirmed cases reported as of July 23, all mild, and 2,018 patients have recovered [2] - The National Disease Control Bureau and the Guangdong Provincial Health Commission have dispatched expert teams to guide and participate in epidemic prevention efforts, focusing on cutting community transmission and preventing the spread of the outbreak [2] Group 3 - Multiple A-share listed companies are developing testing solutions for Chikungunya virus, primarily for research purposes or overseas markets. Ayhuilong's partner company has developed a rapid screening kit, while Shuoshi Biology and Aotai Biology also have testing kits available for research use [3] - Currently, there are no approved Chikungunya testing kits in the domestic market, but the approval process for related testing products is expected to accelerate [3] - Rainbow Group offers a wide range of household insecticide products aimed at mosquito control, including electric mosquito repellent and aerosol insecticides, which utilize high-quality active ingredients recommended by WHO [3]

Core Viewpoint - The article discusses the outbreak of Chikungunya fever in China and globally, highlighting the urgent need for effective detection and prevention measures due to the lack of specific treatments and vaccines [2][3]. Group 1: Current Situation - As of July 23, 2025, Foshan reported a total of 3,645 confirmed cases of Chikungunya fever, with the Shunde District accounting for 3,317 cases, an increase of 383 cases from the previous day [2]. - The World Health Organization (WHO) has warned that 119 countries and regions are experiencing virus transmission, with approximately 5.5 million people at risk of infection, potentially straining healthcare systems [2]. Group 2: Prevention and Control - There are currently no specific drugs or vaccines for Chikungunya fever; the primary prevention strategy is mosquito control, including eliminating breeding sites and using personal protective measures [3]. - The clinical features of Chikungunya fever include acute fever, severe joint pain, and rash, with higher risks for children, the elderly, and immunocompromised individuals [3]. Group 3: Diagnostic Methods - Common diagnostic methods for Chikungunya fever include serological testing, nucleic acid testing, and virus isolation, with specific timelines for sample collection to ensure accurate results [4]. - Currently, there are no approved test kits for Chikungunya fever in China, which poses a challenge for timely diagnosis [4]. Group 4: Market Opportunities - Several domestic companies, including DaAn Gene, Wanfu Biology, and Shengxiang Biology, are developing Chikungunya fever detection solutions based on PCR methodologies, with others exploring high-throughput sequencing and antigen-antibody detection methods [5]. - The ongoing outbreak is expected to accelerate the accumulation of clinical data for these detection products, potentially speeding up their approval and market entry [5].